6KB Stock Overview
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kinnate Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.12 |
| 52 Week High | US$6.80 |
| 52 Week Low | US$1.01 |
| Beta | 1.33 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -66.88% |
| 3 Year Change | -92.37% |
| 5 Year Change | n/a |
| Change since IPO | -93.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6KB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.8% |
| 1Y | -66.9% | -15.8% | 1.0% |
Return vs Industry: 6KB underperformed the German Biotechs industry which returned -21.5% over the past year.
Return vs Market: 6KB underperformed the German Market which returned -1.2% over the past year.
Price Volatility
| 6KB volatility | |
|---|---|
| 6KB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6KB's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 6KB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 94 | Nima Farzan | www.kinnate.com |
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Kinnate Biopharma Inc. Fundamentals Summary
| 6KB fundamental statistics | |
|---|---|
| Market cap | €111.63m |
| Earnings (TTM) | -€118.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs 6KB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6KB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$127.15m |
| Earnings | -US$127.15m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.70 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6KB perform over the long term?
See historical performance and comparison